01—Abstract
Summary
Summary of the 8-K filed June 1, 2026. Cited figures are marked; the original filing is the authoritative source.
Humana Inc. (HUM) filed a Form 8-K on June 1, 2026 under Item 7.01 (Regulation FD Disclosure) to announce that members of its senior management team are scheduled to meet with investors and analysts at various meetings between June 1, 2026 and June 30, 2026.
At these meetings, the Company intends to reaffirm its FY 2026 guidance of at least $8.36a in diluted GAAP earnings per share or at least $9.00 in Adjusted (non-GAAP) earnings per share. The filing states this guidance is consistent with the guidance issued in Humana's press release dated April 29, 2026. The filing includes a reconciliation from GAAP EPS to Adjusted EPS for FY 2026.
The adjustments are amortization of identifiable intangibles of $0.30b, put/call valuation adjustments associated with non-consolidating minority interest investments of $(0.28), value creation initiatives of $0.81, and a cumulative net tax impact of $(0.19). The Company states it does not expect changes to its FY 2026 Adjusted EPS guidance, but it does expect potential changes to its FY 2026 GAAP EPS guidance due to ongoing value creation and other strategic initiatives.
For investors, the key takeaway is that Humana is reaffirming, rather than changing, its previously issued full-year 2026 earnings outlook ahead of investor meetings in June. The filing also flags that GAAP EPS guidance may move while Adjusted EPS guidance is expected to hold, so the gap between the two measures is one to watch.
02—Key points
Key Highlights
- Humana plans to reaffirm FY 2026 guidance of at least $8.36 diluted GAAP EPS and at least $9.00 Adjusted (non-GAAP) EPS during investor and analyst meetings from June 1 to June 30, 2026.
- The reaffirmed guidance is consistent with the outlook in Humana's April 29, 2026 press release.
- GAAP-to-Adjusted EPS reconciliation for FY 2026 includes amortization of identifiable intangibles of $0.30 per share.
- Adjustments include put/call valuation adjustments on non-consolidating minority interest investments of $(0.28) per share and value creation initiatives of $0.81 per share.
- Cumulative net tax impact of $(0.19) per share is included in the reconciliation.
- The Company does not expect changes to FY 2026 Adjusted EPS guidance but does expect potential changes to FY 2026 GAAP EPS guidance from ongoing value creation and strategic initiatives.
- The disclosure is made under Item 7.01 (Regulation FD Disclosure), so the information is furnished rather than a new earnings announcement.
03—Questions
Frequently Asked Questions
What EPS guidance is Humana reaffirming for fiscal year 2026?
Humana intends to reaffirm guidance of at least $8.36 in diluted GAAP earnings per share and at least $9.00 in Adjusted (non-GAAP) earnings per share for the year ending December 31, 2026.
Is this guidance different from what Humana previously announced?
No. The filing states the reaffirmed guidance is consistent with the guidance issued in Humana's press release dated April 29, 2026.
What adjustments bridge GAAP EPS to Adjusted EPS for 2026?
The reconciliation includes amortization of identifiable intangibles of $0.30, put/call valuation adjustments on non-consolidating minority interest investments of $(0.28), value creation initiatives of $0.81, and a cumulative net tax impact of $(0.19).
Will Humana change its Adjusted EPS guidance?
The Company states it does not expect changes to its FY 2026 Adjusted (non-GAAP) EPS guidance.
Could Humana's GAAP EPS guidance change?
Yes. The Company says it does expect potential changes to its FY 2026 GAAP EPS guidance due to its ongoing value creation and other strategic initiatives, and that GAAP guidance excludes the impact of value changes that have not yet been recognized or cannot currently be reasonably estimated.
04—Continue